Our collective results show, for the first time, that the chaperone Artemin could significantly inhibitaggregation of the TAU proteins in a dose-dependent manner, and support Artemin as a potential potent blocker of TAUaggregation in people with AD. The gene discussed is ARTN; the disease is Alzheimer disease.